Abstract
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.
Cite
CITATION STYLE
APA
Achar, J., Hewison, C., Cavalheiro, A. P., Skrahina, A., Cajazeiro, J., Nargiza, P., … du Cros, P. (2017). Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis. Emerging Infectious Diseases, 23(10), 1711–1713. https://doi.org/10.3201/eid2310.170303
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free